February 3, 2014 | Israeli company MediWound, which develops treatments for burns and wounds, has announced that it has filed a draft prospectus for an offering on Nasdaq. The company will hold the IPO at a company value of $400 million (before money) and attempt to raise $100 million. The majority shareholder of the company is Clal Biotechnology.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli Cybersecurity Startup To Provide Training For IDF
October 10, 2024
Johnson & Johnson Completes Purchase Of Israeli Startup V-Wave
October 10, 2024
Weizmann Researchers Create Biodegradable Composite Plastic
October 09, 2024
IIA Funds Further Israeli R&D Into Crustacean Gene Modification
October 09, 2024
Facebook comments